cyrilzakka/clinical-trials huggingface dataset:
Breastfeeding Education in the Time of COVID-19

This project will establish that pediatric and family medicine residents who complete a hybrid breastfeeding medicine curriculum that includes an asynchronous unfolding case scenario along with telesimulation with a standardized patient (SP) will provide timely, skilled lactation support more frequently than residents randomized to an asynchronous unfolding case scenario followed by videoconference group discussion regarding care for the breastfeeding dyad.

1. Establish that pediatric and family medicine residents who complete a novel breastfeeding medicine curriculum that includes an online unfolding case scenario along with telemedicine simulation with a standardized patient (SP) will provide timely, skilled lactation support more frequently than residents randomized to an online unfolding case scenario followed by traditional didactic breastfeeding case-presentation via videoconference.
2. Establish that online learning via unfolding case scenario and telemedicine simulation with a SP will be feasible for family medicine and pediatric residents to complete during their newborn nursery rotation.

Intern and third year residents completing their newborn nursery rotation at UC Davis Medical Center will be cluster-randomized by rotation month to receipt of breastfeeding education via telesimulation with standardized patient or traditional case-based learning via videoconferencing with pediatric faculty. The primary outcome of this study will be the translation of clinical lactation skills to the care of breastfeeding mothers and newborns. I hypothesize that pediatric and family medicine residents randomized to complete the telesimulation with SP will translate their acquired clinical lactation skills to the care of breastfeeding mothers and newborns at a greater rate than residents who complete a videoconference case-based traditional curriculum discussion with a newborn nursery pediatrician.

Eligibility Criteria:
1. Inclusion Criteria: Pediatric and Family Medicine resident physicians at UC Davis Medical Center
2. Exclusion criteria: Individuals who are unable to communicate in English, Individuals who do not have access to videoconferencing via computer or phone.
Nicotinamide Riboside in Hospitalized Patients

Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined

Patients experiencing acute illness will often have a prolonged recovery time. The cause of this is unknown, but certain factors, like age, duration, and graveness of the illness, is associated with prolonged recovery. In this study, we will investigate whether nicotinamide riboside can shorten the recovery phase and improve outcome after acute illness.

Eligibility Criteria:
Inclusion criteria:

1. Adults \> 18 years old, admitted to hospital with tissue damage, can be included when they are considered medically stable though still expected to remain hospitalized for at least 7 more days (from inclusion).
2. Preferably: Previously included in the Janus Cohort or any other cohort or study with stored biological samples.

Exclusion Criteria:

1. Allergy to NR or ingredients in capsules or placebo.
2. Patients expected to pass away within 90 days.
3. Patients unable to give their consent
4. Unstable patients:

   i. Uncontrolled infection (clinical septicaemia, inadequate response to treatment, inadequate control of source of infection or at treating physician's discretion).

   ii. Mean arterial pressure \<70 mm Hg and symptoms of hypotension. iii. Patients requiring dialysis at the time of inclusion or glomerular filtration rate \<40 iv. Liver failure with Child-Pugh class B or C or any class associated with hepatic encephalopathy (any grade), alanin aminotransferase or aspartate aminotransferase \>3 times upper limit v. Moderate to severe peripheral oedema and/or pulmonary oedema, any unstable cardiac rhythm, myocardial infarction with peak TNT \>300 past week. Signs of elevated intracranial pressure (headache, vomiting and depressed global consciousness in conjunction with focal neurological signs, papilledema, spontaneous periorbital bruising and a triad of bradycardia, respiratory depression and hypertension).

   vi. Arterial pH \<7.30 or \>7.50 vii. Serum potassium under 3,2 or over 5 mmol/L.
5. Pregnancy or breastfeeding \*
6. Any cancer not in full remission for \>10 years
7. Use of St John's Wort based supplements during the past 30 days
8. Patient has undergone solid organ transplantation
9. Participation in any clinical trial with unknown medications
10. Major gastrointestinal or other internal bleeding past week
11. Logistical challenges after discharge. Patient must be able to attend follow up.
12. The treating physician considers the patient unfit or unable to participate. \*All fertile women must have a human chorionic gonadotropin test.
Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. The investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. Results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections.


Eligibility Criteria:
Inclusion Criteria:

* have opioid use disorder
* have a severe injection related infection requiring antibiotics
* willing to accept buprenorphine treatment
* anticipated to be discharged home
* require IV antibiotic therapy

Exclusion Criteria:

* stroke or cerebral mycotic aneurysms preventing aortic or mitral valve surgery
* fungal valve IE
* requiring in-patient rehabilitation
* current pregnancy
* hypersensitivity or allergy to buprenorphine
* class III or IV heart failure
* end-stage liver or renal disease
* any condition that may prevent the volunteer from safely participating in the study
* self-report of desire to inject into the PICC line
* pending legal action that could interfere with study participation
* unsafe or unstable environment precluding safe administration of IV antibiotics
* living more than a 60 minute drive outside of Lexington, KY
BRAVA: Building Resilience and Attachment in Vulnerable Adolescents

The prevalence of suicidal ideation (SI) among adolescents in North America is high, making it critical to develop evidence-based brief interventions for adolescents with SI that target healthy coping skills and relationships. BRAVA is a novel brief group intervention for adolescents with mild to moderate SI and their caregivers; youth are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The goal of the randomized controlled trial is to assess the efficacy of a virtually-delivered, brief group intervention for adolescents with mild to moderate SI and their caregivers in reducing SI.


Eligibility Criteria:
Inclusion Criteria:

* Adolescents 13 years old to 17.5 years old
* Mild to moderate suicidal ideation (SI without plan or gesture; 1 on the HEADS-ED) (Cappelli, et al., 2012)
* Interested in study participation
* Access to an electronic device with internet and email capabilities, and a functioning camera and microphone

Exclusion Criteria:

* SI with plan or gesture (2 on HEADS ED; indicated plan or gesture)
* Comorbid disorders (psychosis, schizophrenia, developmental disabilities, major substance abuse, and severe eating disorders).
* Referring clinician has identified an externalizing disorder as a primary diagnosis or primary concern (e.g. Conduct Disorder)
* Currently participating in regular psychotherapy at least one time per week
* Currently under Children's Aid Society care
* Currently in the CHEO ED on a Form 1 or Form 2, or placed on a Section 17.
* Express difficulty with reading and writing
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are asking breast cancer patients who are about to receive treatment or who are currently receiving treatment to tell us what aspects of the app work well, so that they can learn how to improve it.


Eligibility Criteria:
Inclusion Criteria:

Patient Usability Testing Inclusion Criteria:

* History of a cancer diagnosis
* At least 18 years of age
* Male or Female
* The ability to give informed consent in English or Spanish
* Able to use and read a smartphone (iPhone or Android)
* Has a smartphone (iPhone or Android)

Community Usability Testing Inclusion Criteria:

* At least 18 years of age
* Male or Female
* The ability to give informed consent in English or Spanish
* Able to use and read a smartphone (iPhone or Android)
* Has a smartphone (iPhone or Android)

Focus Group and Interview Inclusion Criteria:

* Completed chemotherapy treatment for stage I-III breast cancer.
* Age 18 to 64 (inclusive)
* Female
* Paid employment (full time or part time) in the three months prior to diagnosis or at time of consent to MSK protocol #10-071 (PI: Blinder)
* The ability to give informed consent in English or Spanish
* Able to use and read a smartphone (iPhone or Android)
* Has a smartphone (iPhone or Android)

For Cohort 2:

* Participants was covered by Emergency Medicaid at the time of diagnosis and/or at any point during their treatment for breast cancer

RCT Inclusion Criteria:

* Localized invasive breast cancer (not stage 0 or stage IV) per EMR or breast cancer (not stage 0 or stage IV) per self-report for community participants

  * If electronic medical record does not specify stage and patient is undergoing (neo)adjuvant chemotherapy, assume stage is I, II or III
* Planning to undergo or undergoing adjuvant or neoadjuvant chemotherapy per EMR or planning to undergo or undergo chemotherapy per self-report for community participants
* Age 18 to 64 (inclusive)
* Female
* Employment statue of (full time or part time) (those who are on disability leave/medical leave, and other unique employment circumstances at the PI's dicretion are eligible)
* Language preference as English or Spanish
* Able to use and read a smartphone or tablet (e.g. iPad, iPhone or Android)
* Has access to a smartphone or tablet (e.g. iPad, iPhone or Android)

Exclusion Criteria:

RCT Exclusion Criteria:

* Stage 0 breast cancer (DCIS only)
* Stage IV (metastatic) breast cancer
* Recurrence with metastases of breast cancer
* Participants or family members who are participating in MSK IHCD studies related to social determinants of health
Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica

Acute low back pain is one of the most common reasons for all physician visits(1). Phospholipase A2 (PLA2), a potent inflammatory mediator, has demonstrated to be released by discs following injury(4). Clinical practice and animal research suggest that lumbar radicular pain is the result of inflammation of the nerve root in the epidural space(5). The study will evaluate the efficacy of intravenous Dexamethasone for acute disc herniation-induced sciatica. 40 patients aged 18 years or older, who will be transferred to the emergency room due to sciatic pain will be blindly randomized to receive Dexamethasone 30 mg IV for 3 days an tapering off, 10 mg daily, or normal saline. 20 patients will be in each group. The patients will continue their standard care during the study period. Follow up will last for 3 months. Mann-Whitney test will be used for parametric correlation, Wilcoxon for numeral and x² for categorial variables. Dexamethasone IV can help physicians in treating patients with acute sciatic pain.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years or older presented with acute radicular pain for less than 6 weeks.

Exclusion Criteria:

* Patient with acute infection,
* Psychiatric disorder,
* Uncontroled diabetes,
* Uncontrolede hypertension,
* Severe congestive heart failure,
* Cauda equina syndrome,
* Moderate or severe motor deficit,
* Primary spinal stenosis,
* Pregnancy.
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients

The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in usual clinical practice setting.

Open label

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and above
* Diagnosed with metastatic renal cell carcinoma or gastrointestinal stromal tumor after imatinib treatment failure or intolerance

Exclusion Criteria:

* Subjects with conditions that are contraindicated with sunitinib malate
Open Multi-center Safety & Efficacy Study of Low Frequency Magnetic Fields to Treat Unresponsive Diabetic Foot Ulcers.

An open multicenter trial to document the efficacy and safety of two therapeutic Extremely Low Frequency Magnetic Fields stimulation devices to promote wound healing of Diabetic Foot Ulcers.

An open multi center trial to document the systemic effects and safety of Extremely Low Frequency Electromagnetic Fields (ELF-MF) stimulation on healing of Diabetic Foot Ulcers (DFU). The study will be performed in two sites: Monterrey, Nuevo Leon, with patients from Medical Services of the Autonomous University of Nuevo León, and Cuernavaca, Morelos with patients from Regional General Hospital of Cuernavaca N. 1 IMSS, and Health Services of Morelos.

Two ELF-MF investigational exposure systems will be used to stimulate blood at different anatomical regions to enhance wound healing upon peripheral blood mononuclear cell migration to the ulcer site. a) In Monterrey, Nuevo Leon, where DFU subjects should be exposed at either forearm with a sinusoidal oscillating magnetic field of 120 Hz with nominal ELF-MF amplitude of approximately 0.6mT-0.8mT (6-8 Gauss) RMS 2 hours/day, 2 times/week. and b) In Cuernavaca, Morelos, where DFU subjects would be exposed at the thorax with a stimulation system in a quasi-Helmholtz configuration, for 25 minutes/day, 2 times/week to a sinusoidal oscillating magnetic field of 120 Hz, with nominal ELF-MF amplitude of approximately 0.6mT-0.8mT (6-8 Gauss) RMS. Treatment period for both groups will be 14.2 weeks or upon a complete healing. In each treatment session, evolution of ulcer healing should be recorded photographically.

Efficacy and adverse effects will be searched for during treatment, short-term (\<1 year), and long-term follow-up in both groups (up to 7 years).

Eligibility Criteria:
Inclusion Criteria:

* Age older than 20 years old
* Presence of diabetic foot ulcers resistant to medical and/or surgical treatment
* Medical care prior to admission.

Exclusion Criteria:

* Pregnant women
* Cancer diagnosis
* BMI \> 3
* Non-diabetic leg ulcers
* Infected wounds
* Skin autoimmune disease
* Vasculitis
Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study

A Clinical Trial Study to investigate the potential performance of BTXA on masseter muscle on patient with nocturnal bruxism and to check the pain scale and share this clinical experience.

Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally participated in this study. The patients age 18-60 years. According to the diagnostic grading system of bruxism all subjects will have an assessment including a bruxism questionnaire (i.e., oral history taking with specific focus on bruxism habits) plus a clinical examination to evaluate bruxism signs and symptoms.

Eligibility Criteria:
Inclusion Criteria:

1. Moderate to severe pain in relation to the masseter muscles and TMJ area related to bruxism during clinical examination.
2. Aged 20-60 patients.
3. Tooth-grinding sounds corroborated by family members or caregivers.
4. Cases where bruxism resulted in occlusal surface attrition of posterior teeth

Exclusion Criteria:

1. pain in the orofacial region,
2. insomnia,
3. known botulinum toxin allergy,
4. pregnancy,
5. neuromuscular disease,
6. bleeding disorders,
7. antibiotic therapy,
8. pulmonary disease that produced coughing during sleep,
9. infectious skin lesion at the site of the injection.
Sustained Natural Apophysial Glides (SNAGs) Technique in Non-Specific Neck Pain Patients

Mechanical neck pain is defined for the absence of cervical spinal pathologies.With the SNAGs mobile mobilization method, it reveals effective results in cases of limitation and pain in the cervical joints.Although there are studies with the Mulligan concept in the literature, studies examining the effects of the SNAGs technique on non-specific neck pain are limited.

The aim of this study is to investigate the effectiveness of the Mulligan Concept SNAGs mobilization method applied in addition to the conventional physiotherapy program in individuals with nonspecific neck pain.

This study was conducted to investigate the effectiveness of Mulligan concept cervical sustained natural apophysial glides (SNAGs) mobilization method in addition to the conventional treatment program in patients with nonspecific neck pain. The study included 40 patients (18-50 years of age) with non-specific neck pain, radicular compression and loss of strength for at least 3 months, diagnosed by a specialist physician; patients with central nervous system disease, distal-peripheral nerve injuries Patients with inflammatory joint disease, cervical spine fracture or surgery, patients with upper extremity surgery, cervical spine tumor and infection, cervical spine congenital anomaly and diabetes were not included in the study. 15 sessions were applied for 3 weeks, 5 days a week for 10 weeks, 10 minutes ultrasound, 20 minutes transcutaneous electrical nerve stimulation (TENS) and hotpack application and Mulligan mobilization in addition to physiotherapy programs. The patient was rested for 5 seconds between sets. The physiotherapy program was applied to the control group and the application session was completed. Normal range of motion exercises were performed in both groups and given as home exercise.

Eligibility Criteria:
Inclusion Criteria:

* Volunteer patients with non-specific neck pain lasting at least 3 months,
* Volunteer patients without radicular pressure,
* Volunteer patients with loss of strength,
* Volunteer patients diagnosed with non-specific neck pain by a specialist physician.

Exclusion Criteria:

* Volunteer patients with central nervous system disease,
* Volunteer patients with distal-peripheral nerve injuries,
* Volunteer patients with inflammatory joint disease,
* Volunteer patients with cervical spine fracture or surgery, upper extremity surgery,
* Volunteer patients with vertebrobasilar artery stenosis,
* Volunteer patients with osteoporosis,
* Volunteer patients with cervical dislocation,
* Volunteer patients with cervical spine tumor and infection,
* Volunteer patients with congenital anomalies involving the spine,
* Volunteer patients with patients with diabetes.
Performance of Six Equations for Estimating Resting Energy Expenditure in Patients With Type 2 Diabetes

The present study evaluated the statistical and clinical performance of the six common equations in subjects with type 2 diabetes adopting indirect calorimetry as reference standard

All consecutive subjects with type 2 diabetes referred from June 2012 to December 2019 were eligible. They were excluded if data on ongoing therapy, anthropometric or laboratory parameters, or measured REE was not available or if presenting with conditions known to affect indirect calorimetry.

Eligibility Criteria:
Inclusion Criteria:

* Patients with type 2 diabetes
* Available resting energy expenditure assessed by indirect calorimetry

Exclusion Criteria:

* data on ongoing therapy (e.g. lifestyle measures with or without approved drugs), anthropometric or laboratory parameters (including white blood count, estimated glomerular filtration rate, TSH), or REE assessed by the means of indirect calorimetry could not be retrieved
* presenting with conditions known to affect indirect calorimetry (e.g. patients with strenuous exercise on the day before, asymptomatic patients with severe chronic kidney disease (eGFR \< 30 ml/min/ 1.73 m2), increased white blood count, or subnormal TSH)
Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.

This is a multi-center, single-arm, prospective, observational study. Approximately 70 study participants undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV will be enrolled and followed out to 3 months. Assessments will be conducted at 45 days and 3 months. The evaluation will be conducted at up to 6 sites.

Patients prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after: 1) determination of little to no collateral ventilation between target and ipsilateral lobes and 2) implantation of at least one Zephyr Valve 5.5-LP EBV. Baseline data will be collected retrospectively after enrollment of a patient in the Post-Market Evaluation. Performance and safety of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP will be evaluated post-treatment based on data collected until 3 months after the treatment.

Eligibility Criteria:
Inclusion Criteria:

* Patients with severe emphysema prescribed treatment with Zephyr Valves
* Zephyr Valve Treatment with the use of at least one Zephyr Valve 5.5-LP EBV

Exclusion Criteria:

* Patients determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).
* Patients who undergo Zephyr Valve treatment, but no Zephyr Valve 5.5-LP EBV implanted.
Studies of White Blood Cells Derived From HHT Patients

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study goal is to culture white blood cells that express the proteins mutated in HHT and examine in the laboratory to explain aspects of the HHT disease phenotype.

HHT is a vascular condition but many of the genes that are mutated to cause HHT (endoglin, ALK-1 and SMAD4) are also expressed in white blood cells. In this study, investigators will take blood samples from people with HHT, culture the white blood cells and study their properties in media prompting different types of differentiation, or infection of cell lines with Epstein Barr virus to provide cell lines which can be repeatedly studied. RNA and proteins will be extracted from these cells for study of white cell responses and association with expression levels of endoglin, ALK-1 and SMAD4. The investigators hypothesize that these cells which express "half-normal" endoglin, ALK-1 or SMAD4 will show differences when compared to normal white blood cells. It is also anticipated that that these findings may help to explain aspects of the HHT disease phenotype.

Eligibility Criteria:
Inclusion Criteria:

* Patients with HHT,
* HHT patients family members

Exclusion Criteria:

* Unable to provide informed consent